Epigenomics AG

Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG publishes financial results for fiscal year 2023

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet

Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board

Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Veröffentlichung gemäß § 50 WpHG mit dem Ziel der europaweiten Verbreitung

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company’s Assets and Adjustment of Guidance for 2023

Epigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023

Epigenomics AG: Approval by the Extraordinary General Meeting of the acquisition of almost all assets and corresponding change of the statutory purpose of the Company

Epigenomics AG: Pareto and Warburg publish analyst research reports

Epigenomics AG publishes financial results for the first six months 2023

Epigenomics AG: Capital reduction planned at a ratio of 5 : 1

Epigenomics AG Announces Successful Agreement on the Acquisition of Significant Assets

Epigenomics AG: Agreement on the Acquisition of Almost All Assets

Epigenomics AG: Negotiations on the Acquisitions of Almost All Assets

​​​​​​​Epigenomics AG Reports Financial Results for the First Quarter of 2023

Epigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak Resigns